---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-001383"
form_type: "8-K"
ticker: "BCRX"
cik: "0000882796"
company_name: "BIOCRYST PHARMACEUTICALS INC"
filed_at: "2025-03-11T23:59:59+00:00"
generated_at: "2026-05-25T00:28:28.754065+00:00"
event_type: "litigation"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# BioCryst files patent infringement lawsuit against Annora Pharma over generic ORLADEYO

## Summary
- Annora Pharma sought FDA approval for generic ORLADEYO, challenging three patents expiring in 2039.
- BioCryst filed suit March 10, 2025, in Delaware District Court against Annora, Hetero Labs, Hetero USA, and Camber.
- Lawsuit seeks to enjoin generic launch and order FDA approval only after 2039 patent expiry (including extensions).
- Six other ORLADEYO Orange Book patents expiring in 2035 were not challenged by Annora.
- Company intends to vigorously enforce intellectual property rights protecting ORLADEYO.

## SEC filing metadata
- accession: 0001171843-25-001383
- form_type: 8-K
- ticker: BCRX
- cik: 0000882796
- company_name: BIOCRYST PHARMACEUTICALS INC
- filed_at: 2025-03-11T23:59:59+00:00
- event_type: litigation
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882796/000117184325001383/0001171843-25-001383-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882796/000117184325001383/f8k_031125.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-001383
- JSON: https://secwatch.observer/filing/0001171843-25-001383.json
- Plain text: https://secwatch.observer/filing/0001171843-25-001383.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.